October 23, 2014 1:32 AM ET

Pharmaceuticals

Company Overview of Biozone Pharmaceuticals, Inc.

Company Overview

As of January 2, 2014, Biozone Pharmaceuticals, Inc. was acquired by Cocrystal Discovery, Inc., in a reverse merger transaction. Biozone Pharmaceuticals, Inc., through its subsidiaries, engages in developing and manufacturing over the counter (OTC) drug products, and cosmetic and beauty products on behalf of third parties in the United States and internationally. Its OTC products include hair conditioners and shampoos for treatment of eczema and psoriasis; external analgesics; skin protectants; anti-fungal products; topical anesthetics; nasal sprays; wound care products; acne products; cough and cold products; anti-itch products; and skin lightening products. The company’s cosmetic and beaut...

550 Sylvan Avenue

Suite 101

Englewood Cliffs, NJ 07632

United States

69 Employees

Phone:

201-608-5101

Key Executives for Biozone Pharmaceuticals, Inc.

Biozone Pharmaceuticals, Inc. does not have any Key Executives recorded.

Biozone Pharmaceuticals, Inc. Key Developments

Biozone Pharmaceuticals, Inc. Announces Management Appointments

Biozone Pharmaceuticals, Inc. announced that it has finalized its planned merger with Cocrystal Discovery, Inc. Concurrent with the closing of the merger, Dr. Gary Wilcox has been appointed Chief Executive Officer and Chairman of the Board. Dr. Wilcox previously served on the Board of Directors and was Executive Vice President of Operations at Icos Corporation from 1993 through its sale to Eli Lilly for $2.3 billion in 2007. At Icos he led the team developing Cialis, which now has annual sales over $2 billion. Additionally, Dr. Roger Kornberg, has been appointed Chief Scientist and a Director of the combined entities. Joining Dr. Wilcox and Dr. Fornberg on the Board of Directors is Dr. Phillip Frost, Dr. Sam Lee, Steven Rubin and Dr. Jane Hsiao. Dr. Frost is currently the Chairman and CEO of Opko Health, Inc, and the Chairman of the Board of Teva Pharmaceuticals. Dr. Hsiao is Vice Chairman and Chief Technical Officer of Opko Health, Inc. Additionally, the following individuals were appointed as executive officers of Biozone: Gary Wilcox as Secretary; Sam Lee as President; Gerald McGuire as Chief Financial Officer and Treasurer. Mr. McGuire has served as Cocrystal's interim Chief Financial Officer since April 2012. Elliot Maza, Roberto Prego-Novo and Brian Keller, directors of Biozone, resigned effective at the time of the closing of the Merger. Elliot Maza, Brian Keller and Christian Oertle, the pre-Merger Biozone executive officers, resigned from all of their positions with Biozone.

Biozone Pharmaceuticals, Inc. announced delayed ammended 10-Q filing

On 11/13/2013, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their ammended 10-Q by the deadline required by the SEC.

Biozone Pharmaceuticals, Inc. announced delayed 10-Q filing

On 11/12/2013, Biozone Pharmaceuticals, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Similar Private Companies By Industry

Company Name Region
Disposition Company, Inc. United States
Ndal Manufacturing Industries, Inc. United States
Biologics Process Development, Inc. United States
Iroko Pharmaceuticals Inc. United States
Stason Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 27, 2013
--
Merger/Acquisition
November 13, 2013
Biozone Pharmaceuticals, Inc., Substantially All Assets
Private Placement
October 24, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biozone Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.